{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T21:51:56Z","timestamp":1767649916913},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1471-2334-12-360","type":"journal-article","created":{"date-parts":[[2012,12,19]],"date-time":"2012-12-19T12:14:07Z","timestamp":1355919247000},"source":"Crossref","is-referenced-by-count":14,"title":["QuantiFERON-TB gold in-tube implementation for latent tuberculosis diagnosis in a public health clinic: a cost-effectiveness analysis"],"prefix":"10.1186","volume":"12","author":[{"given":"Maunank","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Miele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"DiPietro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Martins-Evora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Marsiglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Dorman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,19]]},"reference":[{"issue":"RR-9","key":"2171_CR1","first-page":"1","volume":"48","author":"Advisory Council for the Elimination of Tuberculosis (ACET)","year":"1999","unstructured":"Advisory Council for the Elimination of Tuberculosis (ACET): Tuberculosis elimination revisited: obstacles, opportunities, and a renewed commitment. MMWR Recomm Rep. 1999, 48 (RR-9): 1-13.","journal-title":"MMWR Recomm Rep"},{"issue":"9","key":"2171_CR2","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1164\/rccm.2508001","volume":"172","author":"ATS\/CDC\/IDSA","year":"2005","unstructured":"ATS\/CDC\/IDSA: Controlling tuberculosis in the United States. Am J Respir Crit Care Med. 2005, 172 (9): 1169-1227.","journal-title":"Am J Respir Crit Care Med"},{"issue":"RR-6","key":"2171_CR3","first-page":"1","volume":"49","author":"ATS\/CDC\/IDSA","year":"2000","unstructured":"ATS\/CDC\/IDSA: Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep. 2000, 49 (RR-6): 1-51.","journal-title":"MMWR Recomm Rep"},{"issue":"5","key":"2171_CR4","doi-asserted-by":"publisher","first-page":"e36551","DOI":"10.1371\/journal.pone.0036551","volume":"7","author":"M Shah","year":"2012","unstructured":"Shah M, Dipietro D, Greenbaum A, Ketemepi S, Martins-Evora M, Marsiglia V, Dorman SE: Programmatic Impact of QuantiFERON-TB Gold In-Tube Implementation on Latent Tuberculosis Diagnosis and Treatment in a Public Health Clinic. PLoS One. 2012, 7 (5): e36551-10.1371\/journal.pone.0036551.","journal-title":"PLoS One"},{"issue":"1","key":"2171_CR5","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1378\/chest.116.1.104","volume":"116","author":"PO Ozuah","year":"1999","unstructured":"Ozuah PO, Burton W, Lerro KA, Rosenstock J, Mulvihill M: Assessing the validity of tuberculin skin test readings by trained professionals and patients. Chest. 1999, 116 (1): 104-106. 10.1378\/chest.116.1.104.","journal-title":"Chest"},{"issue":"1","key":"2171_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1378\/chest.11-3157","volume":"142","author":"R Diel","year":"2012","unstructured":"Diel R, Loddenkemper R, Nienhaus A: Predictive value of interferon-gamma release assays and tuberculin skin testing for predicting progression from latent TB infection to disease state: a meta-analysis. Chest. 2012, 142 (1): 63-75. 10.1378\/chest.11-3157.","journal-title":"Chest"},{"issue":"3","key":"2171_CR7","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1586\/14737159.6.3.413","volume":"6","author":"M Pai","year":"2006","unstructured":"Pai M, Kalantri S, Dheda K: New tools and emerging technologies for the diagnosis of tuberculosis: part I. Latent tuberculosis. Expert Rev Mol Diagn. 2006, 6 (3): 413-422. 10.1586\/14737159.6.3.413.","journal-title":"Expert Rev Mol Diagn"},{"issue":"3","key":"2171_CR8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.7326\/0003-4819-149-3-200808050-00241","volume":"149","author":"M Pai","year":"2008","unstructured":"Pai M, Zwerling A, Menzies D: Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008, 149 (3): 177-184.","journal-title":"Ann Intern Med"},{"issue":"RR-5","key":"2171_CR9","first-page":"1","volume":"59","author":"GH Mazurek","year":"2010","unstructured":"Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K: Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep. 2010, 59 (RR-5): 1-25.","journal-title":"MMWR Recomm Rep"},{"issue":"1","key":"2171_CR10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S1473-3099(11)70210-9","volume":"12","author":"MX Rangaka","year":"2012","unstructured":"Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J, Fielding K, Wilkinson RJ, Pai M: Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012, 12 (1): 45-55. 10.1016\/S1473-3099(11)70210-9.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"2171_CR11","first-page":"726","volume":"13","author":"D Kunimoto","year":"2009","unstructured":"Kunimoto D, Der E, Beckon A, Thomas L, Egedahl M, Beatch A, Williams G, Tyrrell G, Ahmed R, Brown N, et al: Use of the QuantiFERON-TB Gold test to confirm latent tuberculosis infection in a Canadian tuberculosis clinic. Int J Tuberc Lung Dis. 2009, 13 (6): 726-730.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"20","key":"2171_CR12","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1056\/NEJMsa031667","volume":"350","author":"CR Horsburgh Jr","year":"2004","unstructured":"Horsburgh CR: Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med. 2004, 350 (20): 2060-2067. 10.1056\/NEJMsa031667.","journal-title":"N Engl J Med"},{"issue":"6","key":"2171_CR13","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S1473-3099(11)70069-X","volume":"11","author":"M Pareek","year":"2011","unstructured":"Pareek M, Watson JP, Ormerod LP, Kon OM, Woltmann G, White PJ, Abubakar I, Lalvani A: Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis. Lancet Infect Dis. 2011, 11 (6): 435-444. 10.1016\/S1473-3099(11)70069-X.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"2171_CR14","doi-asserted-by":"publisher","first-page":"340","DOI":"10.7326\/0003-4819-146-5-200703060-00006","volume":"146","author":"D Menzies","year":"2007","unstructured":"Menzies D, Pai M, Comstock G: Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med. 2007, 146 (5): 340-354.","journal-title":"Ann Intern Med"},{"issue":"17","key":"2171_CR15","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1001\/archinte.166.17.1863","volume":"166","author":"KR Page","year":"2006","unstructured":"Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, Federline L, Bur S, Walsh T, Karney W, Milman J, et al: Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med. 2006, 166 (17): 1863-1870. 10.1001\/archinte.166.17.1863.","journal-title":"Arch Intern Med"},{"issue":"6","key":"2171_CR16","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1378\/chest.130.6.1712","volume":"130","author":"A Lardizabal","year":"2006","unstructured":"Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB: Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest. 2006, 130 (6): 1712-1717. 10.1378\/chest.130.6.1712.","journal-title":"Chest"},{"key":"2171_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2466-10-7","volume":"10","author":"A Pooran","year":"2010","unstructured":"Pooran A, Booth H, Miller RF, Scott G, Badri M, Huggett JF, Rook G, Zumla A, Dheda K: Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis. BMC Pulm Med. 2010, 10: 7-10.1186\/1471-2466-10-7.","journal-title":"BMC Pulm Med"},{"issue":"11","key":"2171_CR18","first-page":"1374","volume":"14","author":"H Kunst","year":"2010","unstructured":"Kunst H, Khan KS: Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review. Int J Tuberc Lung Dis. 2010, 14 (11): 1374-1381.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"12","key":"2171_CR19","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1086\/647944","volume":"49","author":"PD Ziakas","year":"2009","unstructured":"Ziakas PD, Mylonakis E: 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis. 2009, 49 (12): 1883-1889. 10.1086\/647944.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"2171_CR20","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1164\/rccm.200901-0153OC","volume":"179","author":"DP Holland","year":"2009","unstructured":"Holland DP, Sanders GD, Hamilton CD, Stout JE: Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med. 2009, 179 (11): 1055-1060. 10.1164\/rccm.200901-0153OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"2171_CR21","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1001\/archinternmed.2008.524","volume":"169","author":"MA de Perio","year":"2009","unstructured":"de Perio MA, Tsevat J, Roselle GA, Kralovic SM, Eckman MH: Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers. Arch Intern Med. 2009, 169 (2): 179-187. 10.1001\/archinternmed.2008.524.","journal-title":"Arch Intern Med"},{"issue":"4","key":"2171_CR22","first-page":"555","volume":"60","author":"WHO","year":"1982","unstructured":"WHO: Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ. 1982, 60 (4): 555-564.","journal-title":"Bull World Health Organ"},{"issue":"15","key":"2171_CR23","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1001\/archinte.1995.00430150057006","volume":"155","author":"RE Brown","year":"1995","unstructured":"Brown RE, Miller B, Taylor WR, Palmer C, Bosco L, Nicola RM, Zelinger J, Simpson K: Health-care expenditures for tuberculosis in the United States. Arch Intern Med. 1995, 155 (15): 1595-1600. 10.1001\/archinte.1995.00430150057006.","journal-title":"Arch Intern Med"},{"key":"2171_CR24","unstructured":"Maryland TB: Statistics, Department of Health and Mental Hygiene. \n                    http:\/\/ideha.dhmh.maryland.gov\/CTBCP\/statistics.aspx\n                    \n                  ,"},{"issue":"9","key":"2171_CR25","first-page":"1209","volume":"14","author":"I Harstad","year":"2010","unstructured":"Harstad I, Winje BA, Heldal E, Oftung F, Jacobsen GW: Predictive values of QuantiFERON-TB Gold testing in screening for tuberculosis disease in asylum seekers. Int J Tuberc Lung Dis. 2010, 14 (9): 1209-1211.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"2171_CR26","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1164\/rccm.201006-0974OC","volume":"183","author":"R Diel","year":"2011","unstructured":"Diel R, Loddenkemper R, Niemann S, Meywald-Walter K, Nienhaus A: Negative and positive predictive value of a whole-blood interferon-gamma release assay for developing active tuberculosis: an update. Am J Respir Crit Care Med. 2011, 183 (1): 88-95. 10.1164\/rccm.201006-0974OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"2171_CR27","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1164\/rccm.200711-1613OC","volume":"177","author":"R Diel","year":"2008","unstructured":"Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A: Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med. 2008, 177 (10): 1164-1170. 10.1164\/rccm.200711-1613OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"15","key":"2171_CR28","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1001\/jama.1996.03540150055031","volume":"276","author":"MC Weinstein","year":"1996","unstructured":"Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB: Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996, 276 (15): 1253-1258. 10.1001\/jama.1996.03540150055031.","journal-title":"JAMA"},{"key":"2171_CR29","unstructured":"Life Expectancy Tables. \n                    http:\/\/www.cdc.gov\/nchs\/fastats\/lifexpec.htm\n                    \n                  ,"},{"key":"2171_CR30","unstructured":"Reported Tuberculosis in the United States. 2009, \n                    http:\/\/www.cdc.gov\/tb\/statistics\/reports\/2010\/pdf\/report2010.pdf\n                    \n                  ,"},{"key":"2171_CR31","unstructured":"Maryland TB Guidelines for Prevention and Treatment of Tuberculosis. \n                    http:\/\/ideha.dhmh.maryland.gov\/OIDPCS\/CTBCP\/CTBCPDocuments\/tbguidelines.pdf\n                    \n                  ,"},{"issue":"10","key":"2171_CR32","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1046\/j.1525-1497.1998.00211.x","volume":"13","author":"DK Owens","year":"1998","unstructured":"Owens DK: Interpretation of cost-effectiveness analyses. J Gen Intern Med. 1998, 13 (10): 716-717. 10.1046\/j.1525-1497.1998.00211.x.","journal-title":"J Gen Intern Med"},{"key":"2171_CR33","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/1472-6963-11-247","volume":"11","author":"A Nienhaus","year":"2011","unstructured":"Nienhaus A, Schablon A, Costa JT, Diel R: Systematic review of cost and cost-effectiveness of different TB-screening strategies. BMC Health Serv Res. 2011, 11: 247-10.1186\/1472-6963-11-247.","journal-title":"BMC Health Serv Res"},{"key":"2171_CR34","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1471-2334-6-47","volume":"6","author":"PK Dewan","year":"2006","unstructured":"Dewan PK, Grinsdale J, Liska S, Wong E, Fallstad R, Kawamura LM: Feasibility, acceptability, and cost of tuberculosis testing by whole-blood interferon-gamma assay. BMC Infect Dis. 2006, 6: 47-10.1186\/1471-2334-6-47.","journal-title":"BMC Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-12-360\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-12-360.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-12-360","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-12-360.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T00:46:25Z","timestamp":1548204385000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-12-360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["2171"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-12-360","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12]]},"article-number":"360"}}